SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529534.
  • 2
    Ankerst DP, Boeck A, Freedland SJ, et al. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol. 2012;30:181187.
  • 3
    Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology. 2006;68:11521155.
  • 4
    Eyre SJ, Ankerst DP, Wei JT, et al. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol. 2009;182:26532658.
  • 5
    Vickers AJ, Cronin AM, Roobol MJ, et al. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010;16:43744381.
  • 6
    National Comprehensive Cancer Network. Prostate cancer early detection. www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection. Updated 2011.
  • 7
    Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27:398403.
  • 8
    Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol. 2009;56:753760.
  • 9
    Nam RK, Kattan MW, Chin JL, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011;29:29592964.